Summary of "Systemic lupus erythematosus EXPLAINED Clearly!"

Systemic lupus erythematosus (SLE) — overview

Systemic lupus erythematosus (SLE), commonly called “lupus,” is a chronic multisystem autoimmune disease. The term reflects historical facial lesions (lupus = wolf) and skin redness (erythematosus); “systemic” denotes whole‑body involvement.

1) Name, epidemiology, and triggers

Term: systemic lupus erythematosus (SLE).
Epidemiology:
- Strong female predominance (~9:1).
- Typical onset during childbearing years (15–44).
- More common and often more severe in people of African, Hispanic/Latino, and Asian descent.
Common triggers believed to unmask genetic susceptibility:
- Ultraviolet (UV) radiation / sun exposure — photosensitivity and flares.
- Certain medications can cause drug‑induced lupus (classically procainamide, hydralazine, isoniazid); this usually resolves after stopping the drug.
- Infectious triggers (e.g., Epstein–Barr virus) via molecular mimicry.

2) Pathogenesis — core concepts

Autoimmunity centered on hyperactive B lymphocytes producing autoantibodies.
Key pathological sequence:
1. Autoantibody production (especially anti‑nuclear antibodies) leads to immune complex formation.
2. Immune complexes deposit in small vessels and organs (notably the renal glomeruli).
3. Complement activation and recruitment of inflammatory cells (neutrophils, macrophages).
4. Persistent low‑grade inflammation causes chronic tissue damage.
5. Impaired clearance of apoptotic cell debris exposes nuclear antigens and amplifies autoimmunity.

3) Characteristic autoantibodies and their significance

ANA (anti‑nuclear antibody): very sensitive screening test; required as an entry criterion in the 2019 EULAR/ACR classification. Common but not specific.
Anti‑dsDNA (anti–double‑stranded DNA): highly specific for SLE; levels often correlate with disease activity and lupus nephritis.
Anti‑Sm (anti‑Smith): highly specific for SLE; diagnostic when present in the appropriate clinical context.
Anti‑Ro/SSA and Anti‑La/SSB: associated with photosensitivity and subacute cutaneous lupus; implicated in neonatal lupus and congenital heart block.
Antiphospholipid antibodies (anti‑cardiolipin, lupus anticoagulant, anti–beta2‑glycoprotein I): define antiphospholipid syndrome (APS) when clinically relevant — increased risk of venous/arterial thrombosis and pregnancy loss.

4) Clinical manifestations — multisystem presentation

Constitutional:
- Profound fatigue (often described as “bone‑deep”), low‑grade fever, raised inflammatory markers (ESR, CRP can be elevated).
Musculoskeletal:
- Arthralgia, non‑erosive inflammatory arthritis (small joints of hands/feet); Jaccoud’s arthropathy (reducible deformities).
Skin and mucosa:
- Malar (“butterfly”) rash across cheeks and nose — photosensitive.
- Discoid lesions: coin‑shaped scarring plaques that can cause permanent scarring and scalp alopecia.
- Oral ulcers (often painful, on the hard palate or buccal mucosa).
Vascular:
- Raynaud’s phenomenon (color changes of digits with cold/stress).
Renal:
- Lupus nephritis (≈30% clinically): proteinuria, oliguria, nephritic or nephrotic presentations, risk of progression to end‑stage renal disease if untreated.
Cardiopulmonary:
- Pleuritis, pericarditis (pleuritic chest pain), myocarditis, Libman–Sacks (sterile) endocarditis; accelerated atherosclerosis and increased coronary artery disease risk.
Bone:
- Osteoporosis (chronic inflammation and long‑term corticosteroids); avascular (aseptic) necrosis of bone (often femoral head).
Hematologic:
- Anemia of chronic disease (normochromic, normocytic), leukopenia, thrombocytopenia.
Neuropsychiatric:
- Cognitive dysfunction (“lupus fog”), headaches, seizures, peripheral neuropathies; rare associations such as Guillain–Barré–like syndromes.
Gastrointestinal:
- Nonspecific symptoms (nausea, vomiting, abdominal pain, hepatomegaly); less commonly lupus enteritis, pancreatitis, or serositis/peritonitis.

5) Diagnostic approach — checklist and scoring concepts

No single diagnostic test; diagnosis combines clinical features and laboratory findings.
Practical approach:
1. Screen with ANA (high sensitivity). In the 2019 EULAR/ACR system, a positive ANA is required as an entry criterion.
2. If ANA positive or suspicion high, test specific antibodies (anti‑dsDNA, anti‑Sm, anti‑Ro/SSA, anti‑La/SSB, antiphospholipid antibodies) to increase specificity and for prognostic implications.
Classification systems:
- SLICC criteria: older checklist style — classification if ≥4 of 17 criteria (including at least one clinical and one immunologic criterion).
- 2019 EULAR/ACR criteria: require positive ANA as entry, then weighted scoring of clinical and immunologic items; diagnosis/classification if cumulative score ≥10 with at least one clinical criterion.
Test for antiphospholipid antibodies when there is thrombosis or pregnancy loss/suspected APS.

6) Treatment framework — “pyramid” strategy

Principle: control symptoms and flares and limit organ damage while minimizing medication toxicity. Use the lowest effective therapy and steroid‑sparing approaches when possible.

Typical tiers (base → top):

NSAIDs: symptomatic relief for mild musculoskeletal pain and fever.
Antimalarials: hydroxychloroquine is a mainstay — effective for skin disease, arthralgia, fatigue, and reduces flares; often used long‑term.
Corticosteroids: rapid control for flares and organ‑threatening disease (e.g., kidney, CNS). Use the lowest effective dose for the shortest duration feasible.
Conventional immunosuppressants: for moderate–severe or organ‑threatening disease and as steroid‑sparing agents (examples: azathioprine, mycophenolate mofetil, cyclophosphamide).
Biologics: targeted therapies for refractory disease (example: belimumab — anti‑BAFF monoclonal antibody to reduce B‑cell activation).
Note: drug‑induced lupus generally improves after stopping the offending medication.

7) Key clinical lessons / takeaways

SLE is protean; suspect it in patients (especially women of childbearing age and higher‑risk ethnic groups) with unexplained fatigue, joint pain, characteristic rashes, or multisystem symptoms.
Use ANA as a screening test but rely on specific autoantibodies and clinical criteria for diagnosis.
Early recognition and appropriate use of antimalarials, immunosuppression, and steroid‑sparing strategies reduce flares and organ damage.
Monitor for serious complications (renal disease, thrombosis from APS, severe cardiopulmonary or neuropsychiatric involvement) and manage accordingly.
Preventive measures: sun protection to reduce photosensitive flares and careful medication review to avoid drugs that may induce lupus.

8) Errors and clarifications from autogenerated subtitles

Several drug and disease names in the subtitles were misspelled; corrected terms used above:
- “prokanomide” → procainamide
- “hydraazine” → hydralazine
- “isazad” → isoniazid
- “bimamap” → belimumab
- “glomemeili” → glomeruli
Diagnostic systems referenced: SLICC and 2019 EULAR/ACR (sometimes called ACR/EULAR 2019).